Related Experiment Video

Updated: Oct 19, 2025

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
05:57

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Published on: May 17, 2024

893

Efficacy and safety of Zhen Wu Decoction against chronic heart failure: A protocol of randomized, double-blinded, and

Jian Liang1, Xianming Tao, Dabi Hu

  • 1The People's Hospital of Dazu, Chongqing Dazu, Chongqing, China.

Medicine
|September 24, 2021
PubMed

Insights

This study evaluates Zhen Wu Decoction (ZWD) for chronic heart failure (CHF). It assesses ZWD

Area of Science:

  • Cardiology and Traditional Chinese Medicine

Background:

  • Chronic heart failure (CHF) poses a significant threat to patient survival and quality of life, with current treatments having limitations.
  • Despite modern therapies, many patients experience recurrent hospitalizations, inadequate efficacy, and adverse effects.
  • Zhen Wu Decoction (ZWD), a traditional Chinese medicine, is widely used for CHF in China.

Purpose of the Study:

  • To evaluate the efficacy and safety of Zhen Wu Decoction (ZWD) in treating patients with chronic heart failure (CHF).

Main Methods:

  • A prospective, double-blinded, randomized, controlled study design.
  • Participants will be randomized (1:1) into a treatment group (guideline-directed medical therapies + ZWD) and a control group (guideline-directed medical therapies + ZWD simulation).
  • Key efficacy endpoints include left ventricular ejection fraction, cardiac dimensions, NT-proBNP levels, and exercise capacity metrics.

Main Results:

  • Efficacy and safety data will be collected and analyzed.

Conclusions:

  • The study aims to provide evidence on the effectiveness and safety of ZWD for CHF treatment.
Abstract

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
578
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
52
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
537